Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q1 2021 · 10-Q
Revenue$10.46B$10.46B+35.3% vs Q1 2020 Net Income$1.79B$1.79B+217.9% vs Q1 2020 EPS Diluted$1.00$1.00+222.6% vs Q1 2020 Operating Income$2,109,000,000+178.2% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
Free Cash Flowderived$2,240,000,000+531.0% Margins · derivedOperating margin20.2%+10.4 pt vs Q1 2020
Net margin17.1%+9.8 pt vs Q1 2020
ended Mar 31, 2021 · filed May 5, 2021 · 35 d after period end